BioCorRx Inc.

BioCorRx Inc. is a U.S.-based specialty outpatient services and pharmaceutical distribution company that has historically operated addiction recovery and weight-loss related programs, while more recently adding Lucemyra® distribution sales. Its reported revenue streams include clinic access fees, membership/program fees, distribution rights income, and supply/distribution net sales tied to exclusive and nonexclusive distribution agreements. The company also operates through BioCorRx Pharmaceuticals, Inc., which entered into distribution arrangements as part of the USWM LLC Asset Purchase Agreement in March 2025. Despite the new revenue activity, the company remains in an early, financially stressed stage and has disclosed substantial doubt about its ability to continue as a going concern.

−600,5 %

−431,5 %

+10 301,1 %

0.10

0.08

— BioCorRx Inc.
%
Pharmaceutical distribution88% Supply and distribution of Lucemyra® and related product sales under exclusive and nonexclusive agreements.
Clinic access services6% Fees earned from patients treated at licensed clinics that use the company's recovery-related service model.
Membership and wellness programs0% Program fees from the UnCraveRx™ weight loss management offering and related membership services.
Distribution rights and licensing6% Income recognized from rights granted to counterparties and amortization of deferred license revenue.

BioCorRx sells to a mix of clinics, distributors, and end-market patients participating in its treatment and wellness...

  • Licensed clinicsprimary

    Clinics that generate sales/access fees when they treat patients under the company's licensed service model.

  • Pharmaceutical distribution partnersprimary

    Counterparties in exclusive and nonexclusive Lucemyra® distribution agreements that purchase supply or share profits from sales.

  • Program participantssecondary

    Individuals enrolled in UnCraveRx™ and related wellness offerings that generate membership/program fees.

  • License and rights counterpartiessecondary

    Partners that pay for distribution rights or related licensing economics, including deferred revenue arrangements.

The company is headquartered in the United States and its reported revenue disclosures are U.S.-centric...

  • •Headquartered in the United States
  • •Revenue disclosures in the excerpts are primarily U.S.-based
  • •Lucemyra® distribution agreements appear to be executed domestically
  • •Clinic and program activity depends on U.S. healthcare and consumer demand
  • •No country-level revenue split was disclosed in the provided excerpts

BioCorRx's near-term strategy appears centered on monetizing the Lucemyra® asset through distribution agreements while...

01
Scale Lucemyra® distributionshort-term

The new distribution stream is the main source of recent revenue growth and is the clearest path to expanding sales.

02
Secure external financingshort-term

The company disclosed substantial doubt about going concern and said current cash will not fund the next twelve months.

03
Preserve legacy service revenuemedium-term

Clinic access fees and program fees provide diversification while the distribution model is still developing.

BioCorRx faces substantial going-concern and liquidity risk because it has disclosed a working capital deficit,...

critical

Going concern and liquidity shortfall

Management disclosed a working capital deficit, accumulated deficit, and insufficient cash to fund the next twelve months.

Scope
Corporate-level funding and operations
Materiality
high
high

Dependence on Lucemyra® distribution execution

Recent revenue growth is driven primarily by new distribution sales, so any disruption in partner performance or supply could quickly reduce revenue.

Scope
Product distribution
Materiality
high
high

Dilution from equity financing

The company stated it will likely need to raise capital through common stock placements or outside financing.

Scope
Capital structure
Materiality
high
medium

Declining clinic and program demand

The company reported fewer patients at licensed clinics and fewer customers in UnCraveRx™, reducing legacy revenue streams.

Scope
Clinic services and consumer programs
Materiality
medium
Revenue recognition for distribution agreements
Can shift revenue between periods and affect gross margin presentation
Deferred revenue from distribution rights
Affects reported revenue mix and comparability across quarters
Valuation allowance on deferred tax assets
Can materially change tax expense and equity
Debt discount and related-party interest
Can increase reported financing costs and net loss

Vincerx Pharma, Inc.

Pharmaceutical Preparations

BIOMERICA INC

BMRA · In Vitro & In Vivo Diagnostic Substances

BIOREGENX, INC.

BRGX · Services-Computer Programming, Data Processing, Etc.

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

BIOVIE INC.

BIVI · Pharmaceutical Preparations

BIOCRYST PHARMACEUTICALS INC

BCRX · Biological Products, (No Diagnostic Substances)

: 11/08/2026